Brief: Eagle Pharmaceuticals Approves Plan Designed To Improve Operational Efficiencies And Realign Sales & Marketing Expenditures
29/02/2024 13:28
Feb 29 (Reuters) - Eagle Pharmaceuticals Inc EGRX.O :
* EAGLE PHARMACEUTICALS- ON FEB 28, APPROVED PLAN DESIGNED
TO
IMPROVE OPERATIONAL EFFICIENCIES AND REALIGN CO’S SALES &
MARKETING EXPENDITURES
* EAGLE PHARMACEUTICALS- REALIGNMENT PLAN IS EXPECTED TO
REDUCE
THE COMPANY’S CURRENT WORKFORCE BY APPROXIMATELY 36%
* EAGLE PHARMACEUTICALS-ESTIMATES THAT IT WILL INCUR ABOUT
$3.5
MILLION IN CASH CHARGES IN CONNECTION WITH REALIGNMENT PLAN
* EAGLE PHARMACEUTICALS - EXPECTS THAT MAJORITY OF CHARGES
RELATED TO REALIGNMENT PLAN WILL BE RECORDED IN FIRST QUARTER OF
2024
* EAGLE PHARMACEUTICALS-INITIATING IMPLEMENTATION OF
REALIGNMENT
PLAN EFFECTIVE IMMEDIATELY
Source text for Eikon: ID:n0001104659-24-029090
Further company coverage: EGRX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Eagle Pharmaceuticals
See all newsDoes a common heart attack pill help everyone? Studies disagree
Brief: Eagle Pharmaceuticals Says Continuing To Evaluate Its Internal Control Over Financial Reporting
Brief: Nantahala Capital Management, Llc Reports 15.1% Passive Stake In Eagle Pharmaceuticals Inc As Of June 30- SEC Filing
Brief: Eagle Pharmaceuticals Says On May 28, Co Requested Hearing Before Hearings Panel Of Nasdaq, Following Delisting Notice From Nasdaq - SEC Filing
Brief: Eagle Pharmaceuticals Announces Receipt Of Delisting Notification From Nasdaq